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Abstract 
Aims: Current therapies in Parkinson’s disease mainly treat symptoms rather than provide 
effective neuroprotection. We examined the effects of safinamide (monoamine oxidase B and 
sodium channel blocker) on microglial activation and the degeneration of dopaminergic neurons in a 
rat model of PD in vivo, and on microglia in vitro. Methods: Rats received unilateral stereotaxic 
injection of 6-hydroxydopamine into the medial forebrain bundle on day 0: the contralateral side 
served as control. Safinamide or vehicle were delivered from days 0 or 1, for 7 days, via sub-
cutaneous mini-pumps. Results: In vehicle-treated rats 6-hydroxydopamine caused a significant 
increase in the number of activated MHC-II
+
 microglia compared with the contralateral side, and 
only 50% of the dopaminergic neurons survived in the ipsilateral SNc.  In contrast, rats treated daily 
with safinamide 50 and 150 mg/ml (on day 0 or 1) exhibited a significantly reduced number of 
activated microglia (55% reduction at 150 mg/ml) and a significant protection of dopaminergic 
neurons (80% of neurons survived) (p<0.001) compared with vehicle-treated controls.  Rasagiline, a 
monoamine oxidase B inhibitor, and lamotrigine, a sodium channel blocking drug, also protected 
dopaminergic neurons, indicating that safinamide may act by either or both mechanisms.  
Safinamide also reduced the activation of microglial cells in response to lipopolysaccharide exposure 
in vitro. Conclusion: Safinamide therapy suppresses microglial activation and protects dopaminergic 
neurons from degeneration in the 6-hydroxydopamine model of PD, suggesting that the drug not 
only treats symptoms, but also provide neuroprotection. 
 
 
 
 
 
 
 
 
 
 
 
 A
cc
ep
te
d 
A
rti
cl
e
This article is protected by copyright. All rights reserved. 
Introduction 
Degeneration of dopaminergic (DA) neurons in the substantia nigra pars compacta (SNc) is 
one of the pathological hallmarks of Parkinson’s disease (PD).  Multiple factors including: oxidative 
stress [1], excitotoxicity [2], mitochondrial dysfunction [3] and inflammation [4] may be involved in 
the initiation and progression of pathology in PD, so drugs with multiple modes of action may be of 
particular value for neuroprotective therapy.Safinamide is approved in the EU for use in combination 
with dopamine agonists as a symptomatic therapy in PD.  Safinamide's pharmacological activities 
include selective blockade of state-dependent voltage-gated sodium channels [5], inhibition of 
induced glutamate release in vitro and reversible inhibition of monoamine oxidase-B (MAO B) [6].  
This pharmacological profile has suggested possible symptomatic benefits in PD, by increasing DA 
availability through inhibition of its metabolism by brain MAO-B [6], and neuroprotective benefits 
through reduction of sodium influx and excitotoxic glutamate release [6].  More recently there has 
been an appreciation of the role of blockers of voltage gated sodium channels on the activation of 
microglia [7][8], combined with the demonstration that safinamide can markedly reduce microglial 
activation and neuroinflammation in animal models of multiple sclerosis [9].  These observations 
suggest an additional potential role for safinamide in the therapy of PD, and other neurodegenerative 
diseases with significant microglial involvement.  In this report we investigate the effects of 
safinamide in a widely used animal model of PD in which both neuroinflammation and 
neurodegeneration are induced in the SN by focal delivery of the neurotoxin 6-hydroxydopamine (6-
OHDA).  In vitro studies with purified microglia were used to establish a direct effect of safinamide 
on these cells.  The results suggest that both the sodium channel and MAO-B activities of safinamide 
may contribute to a unique profile of efficacy, and that safinamide therapy protects against 
neurodegeneration, in addition to any symptomatic effects. 
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Methods 
6-OHDA lesion induction 
Male Sprague–Dawley rats (Harlan Ltd, UK), 200-230 g on the day of surgery, were housed 
five rats per cage and kept on a 12-h light/dark cycle, with food and water ad libitum.  On arrival 
animals were allowed to acclimatize to the new environment for seven days before any experiments 
were conducted.  Lesions were induced by stereotactic injection of 6-OHDA–hydrogen bromide free 
base (12 μg in final injection volume of 4 μl in 0.1% ascorbic acid/saline solution) into the left 
medial forebrain bundle (mfb), under isoflurane-anesthesia as previously described [10] using the 
following coordinates for the location of the mfb: 2.2 mm posterior, 1.5 mm lateral from bregma, 
and 7.9 mm ventral to the dura, according to the brain atlas of Paxinos and Watson (1986).  The 
contralateral side served as an uninjected control.  All experiments were performed in accordance 
with the UK Home Office Animals (Scientific Procedures) Act (1986) and approved by the local 
ethics committee (University College London). 
 
Drug treatment regimens 
Two treatment regimens were employed.  For the first study, animals received a stereotactic 
injection of 6-OHDA into the left mfb as described above.  The animals were divided randomly into 
three groups (n=6-8 per group) and, to ensure consistent drug levels, subcutaneous osmotic mini-
pumps were implanted (delivery rate: 10 l/hr, 7 days duration) (ALZET, Cupertino, CA), 
containing safinamide 50 or 150 mg/ml, or distilled water as vehicle (calculated delivery of 12 
mg/day or 36 mg/day).  Drug/vehicle release from the pumps is reported by the manufacturer to start 
24 hours after implantation.  The doses were chosen based on previous assays of the blood serum 
concentration (1.4-13.5 µM) of the drug following administration of safinamide by minipump in rats 
for 7 consecutive days in which it was observed that the drug reduced neuroinflammation and 
provided neuroprotection in another model when plasma levels were maintained above 10 µM [9], 
consistent with a sodium channel blocking mechanism (IC50 2-10 µM).  These doses are clinically 
efficacious and tolerated in patients [6] . Safinamide/vehicle treatment (subcutaneous osmotic mini-
pumps as before) was administered for seven consecutive days starting on the same day (day 0) as 6-
OHDA lesion induction, and on day eight after 6-OHDA lesion induction the animals were killed 
under terminal anaesthesia by perfusion fixation.  A seven-day dosing regimen after 6-OHDA 
lesioning was chosen because this duration covers the period over which the majority of DA neurons A
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degenerate, and a high number of activated microglial cells are observed [10].  To validate the 
findings the first study (see above) was repeated. 
For the second study, animals received a stereotactic injection of 6-OHDA into the left mfb 
as described above, and they were then divided randomly into two groups (n=6 per group).  On the 
following day (day 1) osmotic mini-pumps (seven day duration, Alzet, Cupertino, CA) containing 
safinamide 150 mg/ml and/or vehicle were implanted sub-cutaneously and treatment was continued 
for seven consecutive days prior to sacrifice on day nine after 6-OHDA lesion induction.  This study 
was designed to start safinamide treatment after a delay of 48 hours, to rule out possible drug 
interaction with 6-OHDA (which has a short half-life due to rapid oxidation).  The dose of 
safinamide was chosen based on our finding from the first experiment (see results).   
Safinamide combines activity against both MAO B and sodium channels, and so to determine 
whether the effects of safinamide in the preceding studies could be ascribed to one or the other 
mechanism a third experiment was performed to compare the results obtained above with those 
obtained from dosing with the MAO B inhibitor rasagiline, and, in a separate group of animals, with 
the sodium channel blocking agent lamotrigine.  Male SD rats (200-230 g, n=18) were injected on 
day zero with 6-OHDA into the medial forebrain bundle as described above.  The animals were 
divided randomly into three equal groups and, on day two, therapy was initiated with rasagiline (1 
mg/kg one loading dose p.o., followed by 0.5 mg/kg, p.o. once daily for seven consecutive days (see 
[11]).  To select a therapeutically relevant dose for rasagiline reference was made to human 
therapeutic and animal model data.  Because of the irreversible mode of inhibition of rasagiline on 
monoamine oxidases, a low daily dose is used to accumulate significant inhibition of MAO-B 
without troublesome effects on MAO-A.  Thus the recommended dose in PD therapy is 1 mg per day 
(approximately 0.015 mg/kg).  In several reports on studies in rat models rasagiline has been 
reported affect biochemical and cellular processes in the CNS at doses ranging from 0.05 mg/kg/day 
[12] through 0.5 mg/kg/day [13], to 1 and 3 mg/kg/day [14]. Lamotrigine (10 mg/kg p.o. once daily 
for seven days) or vehicle (0.5 % methylcellulose p.o. once daily for seven days).  All animals were 
killed by perfusion fixation (see below) while under deep terminal anaesthesia 9 days after the 6-
OHDA lesion induction.  The doses selected for lamotrigine and rasagiline were based on previous 
reports showing neuroprotective properties in rodent models of PD and clinically relevant and safe 
circulating concentrations in patients [15,16].  The adoption of different routes of drug administration A
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was necessary due to lack of comparable data linking dose and circulating concentration for the 
different agents.  
 
Tissue fixation and collection 
At the end of each individual experiment animals were perfused transcardially with cold, 
phosphate-buffered saline (PBS 0.1M) followed by perfusion fixation with cold (4ºC) 
paraformaldehyde (4% in 0.1M PBS, pH 7.4).  Brains were transferred to 4% paraformaldehyde 
solution (4% in 0.1M PBS, pH 7.4) and kept for 24-48 hours prior to cryoprotection in sucrose 
solution (30% in 0.1M PBS, containing sodium azide (0.1%) as preservative) until the block sank 
(48-72 hours).  Coronal sections (20 µm thick) were cut throughout the entire SN using a cryostat 
and collected as free floating specimens. 
 
Immunohistochemical assessment of dopaminergic neuronal degeneration and microglial 
activation 
Dopaminergic neurons were identified by the immunohistochemical detection of tyrosine 
hydroxylase (TH), as described previously [10]. Briefly, endogenous peroxidase activity in the nigral 
free-floating sections was blocked by incubation in H2O2 (1%) for 30 min.  Nonspecific binding was 
blocked by incubation in normal goat serum (20%, diluted in PBS containing 0.1% Triton X-100) for 
1 hr (Sigma, UK).  Sections were subsequently incubated in rabbit polyclonal anti-TH antibody (Pel 
Freez, USA) diluted 1:1000 in normal goat serum (2% in 0.1% Triton X-100) overnight at room 
temperature.  After washing with PBS with 0.1% Triton X-100, sections were incubated with 
biotinylated secondary antibody (anti-rabbit IgG; Sigma UK) diluted 1:200 in PBS, 0.1% Triton, for 
1.5 h.  After subsequent washes in PBS with 0.1% Triton, sections were incubated for 45 min in 
avidin biotin complex diluted 1:200 in PBS (Vectastain Elite ABC kit; Vector Laboratories, UK).  
Bound antibody was visualized utilizing 3, 3′-diaminobenzidine and hydrogen peroxide substrate.  
Activated microglia were distinguished by the expression of major histocompatibility complex II 
(MHC-II, OX-6 labeling), using a similar protocol to that described for TH, with the following 
amendments.  Non-specific binding was blocked with normal horse serum (5% in PBS), and the 
monoclonal antibody directed against OX-6 (Abcam, UK) was made up in normal horse serum (1%) 
(Sigma) in a dilution of 1:750.  The biotinylated secondary antibody was rat-adsorbed mouse 
monoclonal (Sigma). A
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Image capture and cell counts 
Cell counts were conducted manually using photomicrographs prepared using a light 
microscope connected to a Nikon D300 camera at 10x (objective) magnification.  To ensure non-
biased and complete sampling of the entire SNc, nucleated TH-immunopositive neurons without a 
shrunken cell body were manually counted in both ipsilateral and contralateral hemispheres of the 
brain in each of the stereotactic regions of the SNc (−4.80, −5.30, −5.60, −5.80 and −6.30 mm from 
bregma) [17].  The stereotactic region in each section was determined by examination of the shape 
and distribution of TH immunoreactive
 
neurons at low magnification with reference to a rat brain 
atlas.  For consistency, and to minimize bias, one blinded operator performed all the analysis and 
was tested for the consistency of counting at each stereotactic level of the SNc.  For each animal, 8-
10 sections were counted at each of approximately five stereotactic levels, and the average number 
of neurons per section was determined.  These averages were pooled to give a mean cell count per 
section per group, for the ipsilateral and the contralateral side.  The same approach was utilized to 
count microglial cells in each group.    
 
Statistical analysis of the data 
The data are presented as mean ± SEM.  Statistical significance was calculated by two-way 
analysis of variance (ANOVA) and post-tested with post-hoc parametric Newman-Keuls Multiple 
Comparison test using GraphPad Prism v5.00 (GraphPad software, USA) software.  Differences 
within and between groups were considered statistically significant at p <0.05. 
 
In vitro studies   
Animals and materialsSprague Dawley rat pups (5-6 day old) were bred and reared in house 
from stock animals (Charles River UK, Kent, UK), and were sacrificed in accordance with schedule 
1 of the Animals Scientific Procedures Act (1986) UK.  Primary cultures of rat microglia and 
primary cultures of mixed glia-cerebellar granule neurons were prepared and seeded as previously 
described [18].The cells were used after 1 day in vitro (DIV; microglia) or at least 7 DIV (glial-
neuronal cultures).  Cell culture materials were from Invitrogen (Paisley, UK), FITC-conjugated 
isolectin B4 (ILB4) a marker of microglia [19], was from Sigma and anti-arginase-1, a marker for the 
M2 microglial phenotype characterized as a protective, regenerative phenotype (16;17) was from 
Santa Cruz Biotech (USA). A
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Cell treatment 
Microglia were treated with safinamide (0.2-200 μM) or vehicle solvent (dd sterile H2O) ± 
lipopolysaccharide (LPS, final concentration 2 μg/ml) for 24 h.  We used LPS as an activator of 
microglia as in vivo injection of LPS into the SNc or the striatum has been shown to produce a 
highly appropriate animal model for Parkinson’s disease [20–22]. For immunofluorescence analysis 
of arginase-1 and ILB4 expression, treated microglia were processed using standard 
immunolocalisation protocols, the nuclei counterstained with DAPI, and images captured with a 
Zeiss Axioskop fluorescence microscope and x40 objective, with images captured under the same 
exposure conditions for all fields using Axiovision software. 
Neuronal apoptosis was evaluated with 2,5'-Bi-1H-benzimidazole, 2'-(4-ethoxyphenyl)-5-(4-methyl-
1-piperazinyl)-/ 23491-52-3 (Hoechst 33342) [23], cell death by uptake of propidium iodide (PI). 
The percentage of cell death, determined by the number of PI-positive cells per field of view, was 
expressed as a percentage of the total number of Hoechst-staining cells (all cells per field of view) 
[23]. 
 
Results 
Safinamide treatment protects TH+ve DA neurons in the SNc following 6-OHDA lesion 
induction  
Unilateral injection of 6-OHDA caused approximately 50% loss of DA neurons in the SNc, 
compared with the number of neurons on the control side (p<0.001) in vehicle-treated animals.  
Significantly fewer neurons were lost in animals treated with either low or high doses of safinamide 
delivered by minipumps implanted on the day of 6-OHDA injection (p<0.005 and p<0.001 
respectively; Fig1A, B), with greater protection (approx. 82% of neurons survived) achieved by the 
higher dose.  Surviving neurons did not show morphological changes suggestive of a pre-
degenerative state.  Saline-injected controls showed no significant loss of DA neurons (data not 
shown).  
Safinamide treatment (150 mg/ml) reduces the number of activated microglial cells in the SNc 
in 6-OHDA lesioned animals A
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The number of microglial cells expressing MHC class II (OX6
+
; a marker of activation) was 
significantly increased in the lesioned SNc compared with the contralateral side (p=<0.001; Fig2A).  
The labelled cells were present in the medial and lateral portions of the SNc and they showed 
hypertrophied cell bodies and shortened processes.  Treatment with safinamide at low dose (50 
mg/ml for seven consecutive days starting on the same day as 6-OHDA lesion) had no significant 
effect on the number of activated microglia, but treatment with safinamide at high dose (150 mg/ml) 
caused a significant reduction (by approx. 45%) in the number of activated cells compared with 
vehicle-treated control animals (Fig 2B).  In animals treated with safinamide at either low or high 
dose following 6-OHDA lesion induction, the microglial cells exhibited smaller cell bodies and more 
ramified processes than in vehicle-treated controls (Fig 2B inset). 
Delayed administration of safinamide protects TH+ve dopaminergic neurons and reduces the 
number of activated microglia in the SNc following 6-OHDA lesion induction 
To avoid the possibility that the neuronal and microglial protection was an artefact resulting 
from an unexpected interaction between safinamide and 6-OHDA, the implantation of the 
minipumps was delayed by 24 hours after 6-OHDA injection, thereby allowing an effective drug-
free period of 48 hours in which the lesion could develop (see methods).  In control animals, 
injection of 6-OHDA resulted in the degeneration of approximately 50% of the DA neurons 
(p<0.001), as described above, but even the delayed administration of safinamide at high dose (150 
mg/ml; low dose was not employed) still provided significant neuronal and microglial protection.  
Thus safinamide-treated animals possessed significantly more surviving DA neurons than controls 
lacking safinamide (50% increase; p<0.01) (Fig 3A), and significantly fewer activated (OX6
+
) 
microglial cells (p=<0.01) (Fig 3B).  As before, the microglial cells in safinamide-treated animals 
also had a less activated morphological phenotype. 
Effects of reference molecules rasagiline and lamotrigine on the survival of DA neurons and 
the activation of microglial cells 
Rasagiline and lamotrigine were employed as relatively specific inhibitors of MAO B and 
sodium channels respectively, for comparison with safinamide.  As before, the injection of 6-OHDA 
caused the degeneration of approximately 50% of DA neurons on the ipsilateral side (p<0.001; Fig 
4A), but daily administration of rasagiline starting one day after 6-OHDA injection provided 
significant protection resulting in a 50% increase in the number of surviving neurons (p<0.01).  A
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Interestingly, rasagiline also provided a significant reduction in the number of activated microglial 
cells (p<0.001) (Fig 4B).  Similarly, lamotrigine therapy provided significant neuronal protection, 
with an increase of 37% in the number of surviving neurons (p<0.01) (Fig4A).  Lamotrigine 
treatment also resulted in significantly fewer OX6
+
 microglial cells within the lesion (p<0.001) (Fig 
4B), and the microglial cells exhibited a less activated morphological phenotype (Fig 4C). 
Neuroprotective effect of safinamide in vitro 
Incubation of mixed neuronal-glial cultures with safinamide (0.2 - 20.0 μM) had no 
detrimental effect on cell survival; thus there was no statistically significant difference between cells 
cultured with or without safinamide.  In fact the highest dose of safinamide used appeared to 
enhance cell survival above controls (Fig 5). 
Incubation of the neuronal-glial cultures with 2 μg/ml LPS induced significant cell death after 
24 h, but this was attenuated to control levels by 2-20.0 μM safinamide.  Incubation of primary rat 
cultured microglia with 2 μg/ml LPS for 24 h reduced the expression of arginase 1 observed in 
control, non-stimulated microglia (Fig 6).  However incubation of primary cultured microglia with 2 
μg/ml LPS in the presence of 2μM safinamide promoted enhanced arginase expression as revealed 
by immunofluorescence.  The co-labelling of the cultures with ILB4 was used to confirm that the 
cells were microglia. 
 
Discussion 
In PD, the underlying neurodegenerative processes continue even in treated patients, leading 
to increasingly drastic losses of vulnerable cells and synapses, and disability that cannot be 
adequately controlled with current drugs.  The need for treatments that will reduce the underlying 
cell loss is widely recognized.  Some compounds have been shown to be effective in toxin-induced 
models of DA neuron degeneration, and although none has yet been accepted to provide significant 
neuroprotection in PD patients, a “delayed start” clinical study has suggested that rasagiline 
treatment may have had an effect on disease progression [24]. Thus there is a need for drugs with 
additional neuroprotective activities.  The results described above show that microglial activation 
and DA neuron loss can both be reduced by administration of activity-dependent sodium channel 
blockers (lamotrigine and safinamide), and MAO B inhibitors (rasagiline and safinamide).  A single 
agent combining both of these activities might therefore have potential for long-term benefits in PD 
and other neurodegenerative diseases with involvement of microglial activation.   A
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DA neurons are particularly vulnerable to mitochondrial damage because of their high energy 
demand [25].  This is indeed evident in many PD patients, where there is a well-documented 
deficiency in mitochondrial complex I in the SNc [26].  In the 6-OHDA model of PD one of the 
mechanisms that leads to DA neuronal death is inhibition of mitochondrial complexes and Glinka 
and Youdim [27] have shown in isolated brain mitochondria that complexes I and IV are completely 
inhibited by 6-OHDA.  Such inhibition decreases ATP production resulting in inadequate 
functioning of the Na+/K+ ATPase (the “sodium pump”) which normally consumes the majority of 
ATP production within neurons [28].  This inadequacy results in excessive accumulation of 
intraneuronal sodium ions which can cause reverse-mode operation of the sodium-calcium 
exchanger, thereby importing harmful concentrations of calcium, culminating in neurodegeneration.  
Blockade of sodium channels by safinamide would be expected to promote neuronal survival, as 
observed, by reducing sodium influx and so reducing the likelihood of calcium importation. Several 
sodium channel blocking agents are known to provide neuroprotection in models of multiple 
sclerosis, including flecainide [29], phenytoin [30],[31], lamotrigine [32]and safinamide [9]. The 
protection mediated by safinamide is achieved even with delayed administration of safinamide, 
which indicates that the neuroprotective effect is not due to an interference with 6-OHDA itself, but 
rather that it is the result of the effect of safinamide of neurons and glia.  Such a mechanism is 
supported by the observation that another, more specific, sodium channel blocking agent, 
lamotrigine, had similar neuroprotective effects.  Similarly, Lagrue et al (2007) [33] have shown that 
lamotrigine protects DA neurons in the MPTP model of PD, and lamotrigine also provides axonal 
protection in an animal model of MS [32].  Furthermore, lamotrigine at high doses can reduce 
cortical infarct volume, and protect against global cerebral ischaemia [34]. 
We compared the effect of safinamide in the 6-OHDA model with rasagiline, a MAO-B 
inhibitor commonly used in PD therapy.  Rasagiline administered at 0.5 mg/kg daily p.o. showed 
similar effects on the loss of TH neurons and microglial activation to those of high dose safinamide.  
It is thus possible that MAO-B inhibition is part of the neuroprotective mechanism of safinamide.  
However since a MAO-B-independent neuroprotective mechanism has been postulated for rasagiline 
[35], further investigation is necessary before the role of MAO-B inhibition in the microglial and 
neuroprotective effects reported here for safinamide are fully understood. A
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 The findings show that treatment with high dose safinamide not only protected DA neurons, 
but also significantly reduced inflammation as assessed by a measure of microglial activation, 
namely the expression of MHC class II.  In this study we did not assess whether the microglial 
activation preceded the neuronal degeneration or whether it occurred in response to it, but we have 
previously reported that following 6-OHDA lesion induction microglial activation occurred within 3 
days whereas neuronal loss was detected from day 7 following lesioning [10].  This finding therefore 
indicates that the anti-inflammatory effect of safinamide may be a direct effect on microglia. Low 
dose safinamide provided partial protection of TH neurons, and had a partial effect on microglia with 
changes in size and morphology of individual MHC class II positive cells, without reducing their 
total number. 
Microglial activation can initiate and perpetuate neuronal loss by a release of cytotoxic 
substances, such as pro-inflammatory cytokines and oxygen-derived reactive species that are able to 
induce neuronal cell death in vitro [36] and in vivo [37].  Indeed, LPS-induced microglial activation 
has been associated with the destruction of DA neurons in the SNc [20,21,37] and microglial 
suppression can retard dopaminergic cell death in the SNc in the 6-OHDA model [38].  The 
suppression of microglial activation by safinamide may therefore be clinically important because 
microglia are implicated in causing the neuronal loss in idiopathic PD [4], as they are in the loss 
following MPTP intoxication of humans [39].  Cultured microglia express the Nav1.5 and 1.6 
subtypes [40] and Nav1.5 sodium channels are present on macrophages [40] and furthermore a robust 
increase in the expression of Nav1.6 has been found in activated microglia and macrophages [30] 
associated with phagocytic and migratory activity and cytokine release [41].  Blockade of these 
channels may contribute to the neuroprotective effects of sodium channel blockade, (reviewed in 
[42]).  In addition safinamide enhanced the development of a phagocytic phenotype in microglia in 
vitro, with enhanced arginase-1 expression, features of a neuroprotective microglial phenotype 
sometimes referred to as M2.  These findings of an altered microglial phenotype and reduced 
neurotoxicity concur with the in vivo data presented here.  Furthermore whilst there was a reduction 
in the number of microglia in vivo following safinamide treatment, this was only of those microglia 
positive for OX-6 and does not take into account movement of protective alternatively activated 
microglia which may be negative for OX-6 antigen.  It is possible that the reduction in the number of 
degenerating neurons in safinamide-treated animals may have contributed to the reduction in 
microglial activation. A
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Neuroprotection is one of the unmet needs in PD and current therapies do not address the 
progressive neurodegenerative process.  Our data show that in addition to modulating the symptoms 
in patients[43], safinamide also protects DA neurons and reduces inflammation in the 6-OHDA 
model of PD.  We note that safinamide is now approved for use in PD therapy in Europe and that it 
is well tolerated in these patients at a similar plasma concentration to that shown to be 
neuroprotective in the current study.  
Figure legends 
Figure 1: A: Treatment with safinamide (50 and 150 mg/ml) for 7 days protects TH+ve DA neurons 
in SNc following 6-OHDA lesion induction in comparison with vehicle treated controls. Results are 
expressed as the mean number of TH+ve DA neurons ±SEM in the non-lesioned side of the brain 
(grey bars) compared with the lesioned side of the brain (black bars).  Level of significance was 
determined by repeated measure two-way ANOVA test followed by Newman-Keuls Multiple 
Comparison post-hoc post-test. **p < 0.01, ***p < 0.001, n = 6 animals/per group. B: Upper right: 
TH+ve DA neurons in the non-lesion side of the SN in a vehicle treated animal.  DA neurons show 
normal morphology with intact cell bodies and axons and dendrites (x100). Inset: Healthy multipolar 
TH+ve DA neuron with an intact cell body and processes (x200). Upper left: Degenerating TH+ve 
DA neurons in the SN on the side of the 6-OHDA lesion induction (x100).  Inset: DA neurons are 
morphologically compromised with round and smaller cell bodies and reduced length and number of 
processes (x200). Lower right: TH+ve DA neurons in the non lesion side of SN in safinamide treated 
animals. DA neurons show normal morphology with intact cell bodies and process (x100).  Lower 
left: TH+ve DA neurons in the SN on the side of the 6-OHDA lesion in safinamide treated animals 
(x100). Inset: DA neurons show healthy morphology with intact cell bodies and processes (x200). 
Figure 2: A: Treatment with safinamide (150 mg/ml) for 7 days reduced the number of activated 
OX6+ve microglial cells in the in SNc following 6-OHDA lesion induction in comparison with 
vehicle and low dose safinamide (50mg/ml) treated animals. Results are expressed as the mean 
number of OX6+ve activated microglial cells  ±SEM in the non-lesioned side of the brain (grey bars) 
compared with the lesioned side of the brain (black bars).  Level of significance was determined by 
repeated measure two-way ANOVA test followed by Newman-Keuls post hoc Multiple Comparison 
test . *p < 0.05, **p < 0.01, ***p < 0.001, n = 6 animals/per group. B: Upper right: Very few 
OX6+ve activated microglial cells in the non-lesion side of the SN in vehicle treated animals (x100). A
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Upper left: Increased number of OX6+ve activated microglial cells in the medial and lateral tiers of 
the SNc on the side of the 6-OHDA lesion induction (x100). Inset: Activated microglial cells show a 
hypertrophied cell body and shorter processes (x200).  Lower left image: Following safinamide 
treatment (150mg/ml) the number of OX+ve microglial cells is reduced in the SN on the side of the 
6-OHDA lesion (x100).  Inset: Morphologically OX6+ve cells show smaller cell bodies and more 
ramified processes in the SNc (x200). 
Figure 3: A: Delayed administration of safinamide (150 mg/ml) protects TH+ve DA neurons in SNc 
following 6-OHDA lesion induction in comparison with vehicle treated animals.  Results are 
expressed as the mean number of TH+ve DA neurons ±SEM in the non-lesioned side of the brain 
(grey bars) compared with the lesioned side of the brain (black bars).  Level of significance was 
determined by repeated measure two-way ANOVA test followed by Newman-Keuls post hoc 
Multiple Comparison test .**p < 0.01, ***p < 0.001,  n = 6 animals/per group. B: Delayed 
administration of safinamide (150 mg/ml) reduced the number of activated OX6+ve microglial cells 
in the in SNc following 6-OHDA lesion induction in comparison with vehicle and low dose 
safinamide (50 mg/ml) treated animals. Results are expressed as the mean number of OX6+ve 
activated microglial cells  ±SEM in the non-lesioned side of the brain (grey bars) compared with the 
lesioned side of the brain (black bars).  Level of significance was determined by repeated measure 
two-way ANOVA test followed by Newman-Keuls post hoc Multiple Comparison test, **p < 0.01, 
***p < 0.001,  n = 6 animals/per group. 
Figure 4: A: Treatment with  rasagiline (1 mg/kg one loading dose p.o., followed by 0.5 mg/kg, p.o. 
once daily for seven consecutive days), lamotrigine (10 mg/kg p.o. once daily for seven days) and 
safinamide (150 mg/ml) protected TH+ve DA neurons following 6-OHDA lesion induction 
compared with  vehicle treated animals. Results are expressed as the mean number of TH+ve DA 
neurons ±SEM in the non-lesioned side of the brain (grey bars) compared with the lesioned side of 
the brain (black bars). B: Treatment with rasagiline (1 mg/kg one loading dose p.o., followed by 0.5 
mg/kg, p.o. once daily for seven consecutive days), lamotrigine (10 mg/kg p.o. once daily for seven 
days) and safinamide (150 mg/ml) reduced the number of activated OX6+ve microglial cells in the 
in SNc following 6-OHDA lesion induction in comparison with vehicle treated animals. Results are 
expressed as the mean number of cells ±SEM in the non-lesioned side of the brain (grey bars) 
compared with the lesioned side of the brain (black bars).  Level of significance was determined by A
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repeated measure two-way ANOVA test followed by Newman-Keuls post hoc Multiple Comparison 
test. *p < 0.05, **p < 0.01, ***p < 0.001, n = 6 animals/per group. C: Lamotrigine treatment reduces 
the number of activated microglial cells and the remaining OX6+ve microglia show a less activated 
phenotype with smaller cell bodies and ramified processes compared with the vehicle treated animals 
where OX6+ve microglia are morphologically activated with hypertrophied cell bodies and shorter 
processes (x200). 
Figure 5: Mixed cerebellar glial –neuronal cultures (7 DIV) were treated as follows, ctrl; basal 
untreated cells; solv ctrl, 10µl dd H
2
O, safinamide (0.2-20µM) ± lipopolysaccharide (LPS, 2µg/ml) 
for 24 h. The total number of live cells was determined following fluorescence imaging of Hoechst 
33342 (total cell number) and propidium iodide (for cell death) staining. The percentage of live cells 
per field of view per coverslip was determined and data analysed by ANOVA and paired t-test to 
controls or as indicated. Data from one representative experiment of three and represent the mean ± 
SEM of three coverslips per condition with 20 fields of view per coverslip and levels of significance 
are p<0.01, ** or p<0.05 *. 
Figure 6: Safinamide induces an M2 type phenotype as evidenced by enhanced staining of arginase I, 
a marker of this microglial phenotype. 1-DIV primary rat microglia were untreated (Control) or 
treated with 2 μg/ml lipopolysaccharide (LPS) ± 2μM safinamide (LPS + Saf 2 μM) for 24 h. Fixed 
and permeabilised cells were immunolabelled for arginase-I (red) and the microglial marker ILB4 
(green), with nuclei labelled with DAPI (blue) and images captured by fluorescence microscopy 
using set manual exposures for arginase-I and ILB4 and automatic exposure for DAPI. Left hand 
column, representative low power fields, middle column, Arginase and DAPI, right hand column, 
arginase, DAPI and ILB4 overlay. Scale bar = 50 µm 
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